The FDA said it does not intend to take action against 503B drug compounders for 90 days, or until May 22, “to avoid unnecessary disruption to patient treatment.” Hims & Hers Chief Executive Officer ...

An infant with a fatal genetic disease has survived past the age of 2 with no signs of the condition, thanks to treatment started in the womb.

The vast majority of people who have a substance use disorder (SUD) never seek treatment. At most, 10% of adults with a drug or alcohol use disorder have entered any type of inpatient or outpatient ...

The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...

EXCLUSIVE: The parents of two siblings with a life-limiting condition are waiting in agony to find out if health chiefs will ...

The U.S. Food and Drug Administration approved Mirum Pharmaceuticals' genetic disorder drug on Friday, making it the first ...

SMA Healthcare has announced an expansion at its new Marion County facility. The company is adding more than 45 residential beds to treat patients living with substance use disorders. They will be ...

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with almost 17,000 ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...